What is BioCryst Pharmaceuticals's finished goods?

BioCryst Pharmaceuticals (BCRX) reported finished goods of $6.09M in Q1 2026.

How has BioCryst Pharmaceuticals's finished goods changed year-over-year?

BioCryst Pharmaceuticals's finished goods decreased by 22.8% year-over-year, from $7.89M to $6.09M.

What is the long-term trend for BioCryst Pharmaceuticals's finished goods?

Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's finished goods has grown at a 14.8% compound annual growth rate (CAGR), from $4.81M to $7.28M.

What does finished goods mean?

Completed products ready for sale, valued at the lower of cost or net realizable value.

BioCryst Pharmaceuticals BCRX Finished goods

Finished goods at other companies

ANI PharmaceuticalsANIP

$54.85M-8.6%

Agios PharmaceuticalsAGIO

$3.92M-2.5%

PrecigenPGEN

$1.31M—

HRO

HarrowHROW

$8.43M+54.5%

ALN

Alnylam PharmaceuticalsALNY

$38.98M+18.3%

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's finished goods?: BioCryst Pharmaceuticals (BCRX) reported finished goods of $6.09M in Q1 2026.
How has BioCryst Pharmaceuticals's finished goods changed year-over-year?: BioCryst Pharmaceuticals's finished goods decreased by 22.8% year-over-year, from $7.89M to $6.09M.
What is the long-term trend for BioCryst Pharmaceuticals's finished goods?: Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's finished goods has grown at a 14.8% compound annual growth rate (CAGR), from $4.81M to $7.28M.
What does finished goods mean?: Completed products ready for sale, valued at the lower of cost or net realizable value.